When the pandemic first hit US shores in early 2020, there was pressure to act quickly, particularly among top biopharma companies like Gilead, Roche and Regeneron. They expeditiously repurposed and developed new Covid-19 treatments, reaping billions along the way.
Thanks to the latest dump of former FDA commissioner Stephen Hahn’s emails and text messages, released via the FDA’s FOIA office, the agency offers a peek behind the curtain on who exactly was reaching out to Hahn and other former Trump political figures, what they were requesting and, thanks to hindsight, how those early efforts paid off.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 140,200+ biopharma pros reading Endpoints daily — and it’s free.